Table 1.
Assignment of short- and long-lived patients to our revealed gene expression groups in combination with meta-information about cytogenetic abnormality types and FAB types of the DNMT3A-mutant AML patients from TCGA.
| Expression group | ||||
|---|---|---|---|---|
| EG1 | EG2a | EG2b | EG3 | |
| Group composition | ||||
| Short-lived patients | 0 | 2 | 3 | 16 |
| Long-lived patients | 15 | 7 | 3 | 1 |
| Cytogenetic abnormality types | ||||
| n.a. | 1 | 1 | 0 | 2 |
| 8+ | 3 | 1 | 0 | 0 |
| 7q- | 1 | 1 | 0 | 0 |
| Complex | 1 | 0 | 0 | 1 |
| Complex 5p- | 1 | 0 | 0 | 0 |
| Normal | 7 | 6 | 4 | 14 |
| Normal 8+ | 1 | 0 | 1 | 0 |
| Normal 7q- | 0 | 0 | 1 | 0 |
| FAB types | ||||
| n.a. | 0 | 1 | 0 | 0 |
| M0 | 2 | 0 | 0 | 0 |
| M1 | 5 | 3 | 0 | 3 |
| M2 | 4 | 3 | 0 | 3 |
| M3 | 0 | 0 | 0 | 1 |
| M4 | 3 | 2 | 1 | 6 |
| M5 | 0 | 0 | 5 | 4 |
| M7 | 1 | 0 | 0 | 0 |
See also Supplementary Fig. 1 for an overview of the number of mutated genes per subgroup.